“These results show that inhibitory CARs have very interesting and underappreciated properties that can improve the performance of immune cell therapies,” said Wilson Wong, Ph.D., Professor of ...
Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today ...
Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today ...
Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro. The ...
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a biotechnology company developing next-generation cell and gene therapies using ...
SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary ...
And then there were two. Senti Bio, seeing the end of its cash runway hove into view, has pulled the plug on its liver cancer candidate and narrowed its focus onto two CAR-NK programs to preserve its ...
Data from 20 patients (18 with evaluable responses) were presented at the American Society of Hematology (ASH) Annual Meeting. On Tuesday, the U.S. Food and Drug Administration (FDA) granted ...
Senti Bio released a KOL segment discussing leukemia research and its lead program, SENTI-202, featuring Drs. Strickland and Rajangam. Senti Biosciences, Inc. has released a Virtual Investor KOL ...
SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation ...
Senti Biosciences, Inc. has announced that its CEO, Timothy Lu, participated in Nasdaq's Amplify Spotlight Series, where he discussed the company's proprietary Gene Circuit platform aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results